Welcome to our dedicated page for Zomedica news (Ticker: ZOMDF), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.
Zomedica Corp. (ZOMDF) is an animal health company focused on diagnostic, therapeutic, and monitoring devices for equine and companion animals. This news page aggregates company announcements, product updates, financial disclosures, and strategic communications so readers can follow how Zomedica is executing its stated growth plans in veterinary devices and services.
Recent news highlights Zomedica’s work across multiple platforms. The company has reported launches and expansions within its TRUFORMA in-clinic diagnostic platform, including an equine progesterone assay for reproductive management and feline validation for its multiplexed cobalamin and folate assay. It has also announced enhancements to its VETGuardian Zero Touch monitoring platform through the VETGuardian PLUS monitor, which adds a built-in display, remote viewing, and imaging features to support workflow efficiency in clinics.
On the therapeutic side, Zomedica has issued press releases about the Assisi Loop Lounge tPEMF therapy bed, positioned as an evidence-based, non-pharmaceutical option for pain and inflammation, and has continued to emphasize the role of its PulseVet shock wave system in musculoskeletal healing. News items also cover distribution agreements, such as an expanded partnership with Grovet b.v. in Europe, and collaborations that raise awareness of its Assisi and Calmer Canine technologies.
Investors can also find coverage of Zomedica’s quarterly financial results, including segment performance across diagnostics, therapeutic devices, and development services, as well as liquidity and margin commentary. Regular “Fourth Friday at Four” webinars and related special sessions are announced through press releases, providing additional context on strategy, product platforms, and business performance. Bookmark this page to review Zomedica’s ongoing disclosures and corporate developments over time.
Zomedica (OTCQB:ZOMDF) will host its April "Fourth Friday at Four" investor webinar on April 24, 2026 at 4:00 p.m. ET. The session, "Built to Perform: Inside Zomedica's Manufacturing and Quality Operations," offers a facility video tour and live Q&A covering two U.S. manufacturing sites, automation, and ISO 13485 quality systems.
Attendees will see how in-house manufacturing, an automated TRUFORMA cartridge line, and cross-trained teams support scalable production, consistent quality, and margin optimization across Zomedica's diagnostic and therapeutic product portfolio.
Zomedica (OTCQB:ZOMDF) announced a strategic collaboration with Boehringer Ingelheim to integrate the TRUFORMA diagnostic platform into Boehringer's idPPID™ equine testing program, enabling point‑of‑care eACTH and insulin testing, no‑cost analyzer placement in practices, and reimbursement for diagnostics.
The agreement aims to expand TRUFORMA's installed base, drive recurring cartridge orders, and support earlier PPID detection and monitoring in aging horses.
Zomedica (OTCQB:ZOMDF) reported record Q4 2025 revenue of $10.5M and full-year 2025 revenue of $32.0M, a 17% increase versus 2024. Gross margin was 68% for the year (Q4: 69%), liquidity stood at $53.3M, and new Development Services generated $3.1M in 2025.
Operating expenses excluding a non-cash impairment were down 7% year-over-year, cash burn for 2025 was $18.1M, and reported net loss including impairment was $81.9M.
Zomedica (OTCQB:ZOMDF) will host a live investor webinar on March 27, 2026 at 4:00 p.m. ET to review fourth-quarter and full-year 2025 financial results and present the company's equine-focused product portfolio and market opportunity.
The session will cover equine market scale (U.S. horse industry ~$122 billion; ~60 million horses globally), Zomedica technologies for equine care, and a live Q&A. A replay will be available on the company's Investor Relations site.
Zomedica (OTCQB:ZOMDF) announced a national commercial distribution agreement with Moichor to supply co-branded TRUVIEW digital microscopy systems and consumables to Moichor's point-of-care veterinary customers nationwide. The partnership integrates Moichor's proprietary AI engine and board-certified pathology services, aiming to accelerate system placements and drive recurring consumables revenue.
The agreement expands reach into companion and exotic animal practices and links automated slide preparation, high-resolution imaging, and remote pathology to improve diagnostic consistency and turnaround.
Zomedica (OTCQB:ZOMDF) will host its "Fourth Friday at Four" investor webinar on February 27, 2026 at 4:00 p.m. ET focused on research & development and the company’s innovation pipeline.
The session will review R&D priorities, pipeline advancement, commercial alignment and a virtual tour of the Plymouth R&D facility, followed by a live Q&A. Registration is required.
Zomedica (OTCQB:ZOMDF) announced on January 23, 2026 that its TRUVIEW® digital microscopy system now includes AI diagnostic interpretation for hematology, with skin and ear cytology support to follow shortly. The software-based enhancement is available immediately to existing TRUVIEW subscribers via an over-the-air update through the myZomedica® ecosystem, requiring no new hardware. Zomedica says the AI classifies blood cells, flags abnormalities, and delivers results in minutes, while offering optional telepathology review by board-certified pathologists. The update aims to speed workflows, improve consistency, and leverage the installed base to expand the platform's clinical and commercial relevance.
Zomedica (OTCQB:ZOMDF) entered a contract manufacturing and services agreement with Rahm Sensor Development to produce the Cell-Guardian™, Rahm's first commercial personnel monitoring device. Zomedica will provide manufacturing, engineering services, and Level One customer support, aiming to monetize existing assets, improve utilization, and generate incremental contract-based revenue without increasing fixed costs. The company cited wearable market data (global market ~$84B in 2024, projected to $186B by 2030, CAGR 13.6%) as supportive of measured diversification into adjacent monitoring and sensor markets.
Zomedica (OTCQB: ZOMDF) will host the next installment of its investor webinar series, Fourth Friday at Four, on January 23, 2026 at 4:00 p.m. ET. Titled "Digital Advantage: Powering Scalable Growth Through Innovation," the session will outline Zomedica's expanding digital ecosystem, technology-enabled product pipeline, and initiatives aimed at driving sustainable revenue expansion, operating leverage, and long-term shareholder value. The program includes prepared remarks and a Q&A; investors can register online.
Zomedica (OTCQB:ZOMDF) launched the VETGuardian PLUS monitor on December 30, 2025, the next generation of its Zero Touch patient monitoring platform for veterinary clinics.
Key features include a built-in kennel display, remote clinic-wide viewing, live video with night vision and thermal imaging, flexible mounting, and a more robust design. The product is commercially available immediately in the United States and select international markets through direct sales and distributors.
Market context: Research and Markets estimates the global veterinary monitoring market at approximately $720 million in 2025 with an 8% CAGR through 2029. Zomedica offers an optional upgrade path for existing customers while continuing support and training.